Takeda Pharmaceutical Company Ltd

Insomnia market report forecasts growth from 2020 to 2034, driven by increasing prevalence, awareness, and emerging therapies like Seltorexant and TS-142. Challenges include high treatment costs and patient non-compliance, with unmet needs for long-term solutions with minimal side effects.

The authors thank project team members Natasha Elsner, Apoorva Singh, Steve Davis, Wendy Gerhardt, and Maulesh Shukla, contributors Vicky Levy, Rob Jacoby, Karen Taylor, Jay Bhatt, Terry Koch, Sheryl Jacobson, Mathias Cousin, Gregory Reh, Shoichi Negishi, Teresa Leste, Kathy Haines, Alina Klinova, Cameron McClearn, Kenji Tomino, and Glenn Snyder, subject matter experts Ryan DeMerlis, Maxine LeSaux, Sebastian Payne, Namrita Negi, Leah Micalizzi, Mani Keita Fakeye, Christine Chang, Kate White Walters, Jaya Nagdeo, Chase Langhorne, Diana Francis, Keith Apple, Kristopher Larsen, Lisa Illif, Roxanne Lucy, Anne Phelps, and Shahira Knight, editor Rebecca Knutsen, and interviewees Evan Lippman, Shuhei Sekiguchi, and Akiko Amakawa. Cover image by Sofia Sergi, Getty Images, and Adobe Stock.

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.

Adding daratumumab to VRd improved MRD-negativity rates and PFS in transplant-ineligible/deferred multiple myeloma patients, with MRD-negativity rates increasing by 50% and PFS rates at 54 months being 68.1% vs 49.5%. Daratumumab also doubled sustained MRD-negative CR rates and provided PFS benefits regardless of MRD status.

Filgotinib, an oral JAK inhibitor, met only one of four primary endpoints in a phase III Crohn's disease trial, possibly due to study design issues. Clinical remission was achieved by more patients previously treated with biologics, but endoscopic response was not met. Maintenance phase showed better results, with clinical and endoscopic remission rates improving. Study limitations included early endoscopic assessment and high placebo response rates.

Takeda Pharmaceutical to divest its 49% stake in Teva Takeda Pharma, established in 2016, to Teva, which will then sell the unit to J-Will Partners' subsidiary JKI.

Clinical research professionals are increasingly using AI for drug discovery, data analysis, and patient care, such as AI tools for stroke diagnosis and treatment, machine learning models for trial data interpretation, and AI-driven drug development processes.

EFPIA highlights EU's roadmap for precision oncology to address rising cancer burden, despite forecasted mortality rate declines. Stakeholder roundtable in Brussels aims to improve personalized cancer treatment. EU initiatives, including AI-powered cancer care and the DigiONE pilot, aim to advance precision medicine. A gold-standard cancer data management system is necessary for innovative precision medicine access, emphasizing standardized data formats, robust privacy, and professional education.

The biotech industry is growing rapidly due to advancements in genomic research, personalized medicine, and innovative platforms, with key stocks like HRMY, TRDA, and PBYI leading the charge. The global biotechnology market is projected to reach $4.61 trillion by 2034, driven by increased investment, favorable regulations, and high demand for novel therapies. TRDA specializes in EEV therapeutics for neuromuscular diseases, HRMY focuses on rare and neurological diseases, and PBYI develops cancer treatments, all showing strong financials and growth potential.

Halozyme Therapeutics offers €2 billion to acquire Evotec SE, aiming to combine Halozyme’s drug delivery expertise with Evotec’s drug discovery capabilities, accelerating biologic drug development and expanding global access to affordable treatments. The acquisition, backed by Halozyme’s strong financial position, targets faster market delivery of breakthrough therapies and addresses unmet medical needs in oncology, neurology, and infectious diseases.